Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

BACKGROUND: Bortezomib belongs to a new class of anti-cancer agents, the proteasome inhibitors, and has documented activity in multiple myeloma and mantle cell lymphoma. Preclinical studies suggest that bortezomib has synergistic activity with rituximab, which provides a rationale for the exploratio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lamm, Wolfgang, Kaufmann, Hannes, Raderer, Markus, Hoffmann, Martha, Chott, Andreas, Zielinski, Christoph, Drach, Johannes
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2011
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128220/
https://ncbi.nlm.nih.gov/pubmed/21486866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.041392
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados